dc.contributor.author | Neidle, S | |
dc.contributor.author | Parkinson, G | |
dc.date.accessioned | 2018-09-18T10:36:00Z | |
dc.date.issued | 2002-05 | |
dc.identifier | 5 | |
dc.identifier.citation | NATURE REVIEWS DRUG DISCOVERY, 2002, 1 pp. 383 - 393 | |
dc.identifier.issn | 1474-1776 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/2764 | |
dc.identifier.doi | 10.1038/nrd793 | |
dc.description.abstract | Maintenance of telomeres - specialized complexes that protect the ends of chromosomes is undertaken by the enzyme complex telomerase, which is a key factor that is activated in more than 80% of cancer cells that have been examined so far, but is absent in most normal cells. So, targeting telomere-maintenance mechanisms could potentially halt tumour growth across a broad spectrum of tumour types, with little cytotoxic effect outside tumours. Here, we describe the current understanding of telomere biology, and the application of this knowledge to the development of anticancer drugs. | |
dc.format.extent | 383 - 393 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | NATURE PUBLISHING GROUP | |
dc.title | Telomere maintenance as a target for anticancer drug discovery | |
dc.type | Journal Article | |
rioxxterms.versionofrecord | 10.1038/nrd793 | |
rioxxterms.licenseref.startdate | 2002-05 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | NATURE REVIEWS DRUG DISCOVERY | |
pubs.notes | affiliation: Neidle, S (Reprint Author), Inst Canc Res, Chester Beatty Labs, CRC, Biomol Struct Unit, 237 Fulham Rd, London SW3 6JB, England. Inst Canc Res, Chester Beatty Labs, CRC, Biomol Struct Unit, London SW3 6JB, England. keywords-plus: G-QUADRUPLEX DNA; HUMAN TUMOR-CELLS; CATIONIC PORPHYRINS; SMALL-MOLECULE; POLY(ADP-RIBOSE) POLYMERASE; FISSION YEAST; C-MYC; INHIBITION; LENGTH; END research-areas: Biotechnology & Applied Microbiology; Pharmacology & Pharmacy web-of-science-categories: Biotechnology & Applied Microbiology; Pharmacology & Pharmacy number-of-cited-references: 80 times-cited: 513 usage-count-last-180-days: 8 usage-count-since-2013: 98 journal-iso: Nat. Rev. Drug Discov. doc-delivery-number: 607EB unique-id: ISI:000178777700020 da: 2018-09-18 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR | |
pubs.volume | 1 | |
pubs.embargo.terms | Not known | |
dc.contributor.icrauthor | Neidle, Stephen | en |